2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1289

Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features
Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Abstract Number: 1291

Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Abstract Number: 1292

Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Abstract Number: 1293

Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Abstract Number: 1294

Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Abstract Number: 1295

Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Abstract Number: 1296

Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Abstract Number: 1297

Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies
Abstract Number: 1298

A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis
Abstract Number: 1299

Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults
Abstract Number: 1300

Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials
Abstract Number: 1301

Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts
Abstract Number: 1302

Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Abstract Number: 1303

Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].